Prior authorization — procedure and device codes

Providers must verify prior authorization requirements and submit authorizations where required before scheduling procedures or obtaining devices related to Meniere's disease and related disorders surgery. Covered and non-covered CPT/HCPCS/ICD-10 codes are listed in the policy's coding tables and should be referenced when requesting prior authorization.

• Verify prior authorization for listed CPT codes (e.g., 61590, 61591, 61592, 64716, 69433, 69436, 69676, 69801, 69805, 69806, 69905, 69910, 69915, 69950, 69930) as applicable
• Check HCPCS and device codes (e.g., L8614-L8629, E2120) and coverage status before procurement or billing
• Use policy number 0514 reference when submitting authorization requests

Prior authorization considerations for uncommon/experimental procedures

When requesting prior authorization for uncommon or experimental procedures, include a clear clinical rationale and supporting literature. Procedures identified as experimental/investigational by Aetna (see list) are at high risk of denial; obtain medical director review if pursuing authorization.

• Examples at high denial risk: cochleostomy with neurovascular transplant; intra-tympanic dexamethasone thermo-sensitive gel; positive pressure therapy to improve endolymphatic sac surgery outcomes; simultaneous labyrinthectomy with cochlear implantation; tenotomy of stapedius/tensor tympani; triple semi-circular canal plugging
• Medicare NCD: cochleostomy with neurovascular transplant is not covered

Prior authorization for salvage intratympanic steroid therapy

For sudden sensorineural hearing loss (SSNHL) salvage intratympanic glucocorticoid therapy should be considered only after inadequate response to initial therapy. Timing and prior treatments must be documented when requesting authorization.

• Salvage intratympanic glucocorticoid injections are suggested for patients with <10 dB improvement or persistent ≥20 dB hearing loss after initial therapy
• Treatment is ideally initiated within 6–8 weeks of symptom onset
• If initial therapy was systemic glucocorticoids, intratympanic salvage is appropriate; no additional glucocorticoid therapy if initial treatment included both systemic and intratympanic glucocorticoids

Investigational procedures — denial risk

Aetna considers certain procedures experimental/investigational; requests for these procedures are likely to be denied. Provide strong evidence if seeking exception and expect additional review.

• Procedures listed as investigational include cochleostomy with neurovascular transplant, intra-tympanic dexamethasone thermo-sensitive gel, positive pressure therapy adjuncts, simultaneous labyrinthectomy with cochlear implantation, tenotomy of stapedius/tensor tympani, and triple semi-circular canal plugging
• Medicare does not cover cochleostomy with neurovascular transplant for Meniere's disease per NCD

Insufficient follow-up may affect evidence acceptability

Clinical evidence used to support requests should meet follow-up and reporting standards. Studies with insufficient follow-up were routinely excluded from systematic reviews and may weaken the case for coverage.

• Cochrane-style reviews excluded trials with follow-up <3 months; provide adequate follow-up data when citing studies
• Very low-certainty evidence from small trials may not support coverage for novel approaches

Prior authorization for surgery — selection criteria required

Before scheduling surgical interventions for Meniere's disease, confirm that selection criteria are met. Lack of documentation demonstrating these criteria may result in denial of authorization or payment.

• Selection criteria required prior to surgery scheduling: disabling vertigo; symptoms for ≥2 years; failed conservative management; unilateral disease (labyrinthectomy only when severe–profound hearing loss in involved ear)
• Document failure of dietary (low-sodium, avoid caffeine/alcohol/nicotine) and medical therapies (diuretics, anti-emetics, vestibular suppressants)

No explicit prior authorization requirements stated in some excerpts

Some excerpts in the policy do not state explicit prior authorization or denial rules; in those cases follow standard plan prior-auth processes or contact Aetna for clarification.

• When prior authorization language is not explicit in a section, use the coding tables and Appendix selection criteria as the operational guide
• Contact Aetna provider services or use the member's plan portal to confirm prior authorization requirements

Clinical documentation to justify surgery

Document chronic refractory disease and diagnostic confirmation clearly in the medical record to justify surgical interventions. Provide audiometric and vestibular testing results, duration of symptoms, and prior conservative treatments.

• Document chronicity (≥2 years), disabling vertigo, and failure of conservative therapy
• Provide rationale for chosen surgical approach (destructive vs non-destructive) and risk/benefit discussion

Required clinical documentation for surgical interventions

Required clinical documentation for surgical interventions should include preoperative diagnostic testing, operative details, and objective outcome measures to support medical necessity and for post-operative review.

• Audiometric testing (pure tone audiometry, speech discrimination) and documentation of air–bone gap where relevant
• Vestibular testing results (caloric testing, VEMP thresholds, cVEMP/oVEMP) and vestibular function assessments
• Operative reports describing procedure type, approach (middle fossa, transmastoid), and any device implantation
• Post-operative follow-up data (audiometry, VEMP changes, vertigo control) when available

Preoperative diagnostic testing and documentation for SSCD

For superior semicircular canal dehiscence (SSCD), submit detailed preoperative diagnostic testing: symptom description, audiometry, high-resolution CT, and VEMP testing results to confirm diagnosis and document the target ear for surgery.

• Symptoms: sound- or pressure-induced vertigo, oscillopsia, and demonstration of sound/pressure-evoked eye movements
• Audiometry showing air–bone gap or other relevant findings
• High-resolution CT demonstrating bony dehiscence of the superior semicircular canal
• cVEMP and/or oVEMP thresholds (air- and bone-conducted) showing pathologically lowered thresholds to support diagnosis and to lateralize the worse ear

Required documentation for surgical eligibility

Required documentation for surgical eligibility must confirm disabling vertigo, chronicity of symptoms, and failure of conservative management. Missing these elements may lead to non-coverage for surgical interventions.

• Disabling vertigo documented in history and functional impact
• Symptoms present for at least 2 years
• Evidence of failed conservative management: dietary measures, diuretics, vestibular suppressants, and other medical therapy
• For labyrinthectomy, document unilateral disease with severe-to-profound hearing loss in the involved ear

No documentation requirements present in some excerpts

Some administrative or informational excerpts in the policy contain no explicit documentation requirements. When absent, rely on the policy's coding, selection criteria, and clinical sections for documentation expectations.

• Use policy Appendix and background sections as the primary source for documentation requirements when not restated elsewhere
• Contact Aetna for case-specific documentation guidance if uncertain

Therapeutic sequencing guidance

Therapeutic sequencing should be documented: conservative measures first; for intra-tympanic options weigh methylprednisolone (hearing-preserving) versus gentamicin (vestibular ablation with hearing risk) based on clinical goals and hearing status.

• Document trials of dietary sodium restriction, diuretics, vestibular suppressants, and other medical management prior to intra-tympanic or surgical interventions
• When selecting intra-tympanic therapy, note that glucocorticoids are generally less destructive to hearing than gentamicin and may be preferred when hearing preservation is important

Step therapy for sudden sensorineural hearing loss

Step therapy for SSNHL: initial systemic glucocorticoids are first-line; intratympanic glucocorticoids are an accepted salvage option for inadequate responders. Document prior systemic therapy when requesting intratympanic salvage treatment.

• Initial therapy: systemic glucocorticoids for SSNHL unless contraindicated
• Salvage: intratympanic glucocorticoids within 6–8 weeks for inadequate response to systemic therapy
• If initial treatment included both systemic and intratympanic glucocorticoids, further glucocorticoid therapy is not recommended

No step therapy requirements stated in these excerpts

No formal step therapy requirements beyond those described in the clinical guidance are stated in some policy excerpts; follow the clinical sequencing guidance above and the member's benefit plan for any utilization management rules.

• Where step-therapy language is absent, use standard clinical sequencing (systemic → intratympanic salvage) and confirm any plan-specific utilization management rules
• Contact Aetna for exceptions or case-by-case prior authorization inquiries